Clinical Research on Use of Oxaliplatin in Combination with HCPT, LV and 5FU in a Regimen for Advanced Gastric Cancer

OBJECTIVE To observe the effects and adverse reactions of a OXA-HCPT LV/5FU 3 regimen for patients with advanced gastric cancer.

METHODS OHLF 3 regimen: OXA 130 mg/m²iv d 1, HCPT 6 mg / m², iv d 1~5, LV 200 mg/m²iv 2 h followed by a 5FU 400 mg/m² iv bolus and 5FU 600 mg/m² iv d 1-3, were given, every 21 days as 1 cycle. Assessment of the tumor was conducted after 3 cycles and the effective cases were confirmed after 4 weeks.

RESULTS Among 39 patients, 36 were actually evaluable. Overall response rates (CR + PR) were 50%; the major adverse reactions were mild hematological toxicity, nausea and vomiting and peripheral nerve abnormalities.

CONCLUSION The OHLF 3 regimen using OXA and HCPT Is effective and results in mild toxicity when used In combined chemotherapy for advanced gastric cancer.